stockportfolio.pro
Contineum Therapeutics, Inc. (CTNM)
Healthcare · Biotechnology · NasdaqGS
Contineum Therapeutics, Inc. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $50.00M | $0 | $0 |
| Gross profit | — | — | — | — |
| Net income | $-24.25M | $22.72M | $-42.26M | $-59.98M |
| Net margin | — | 45.4% | — | — |
Source: Contineum Therapeutics, Inc. SEC filings (10-K).
Explore 4 years of Contineum Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track CTNM in your portfolio →
Contineum Therapeutics, Inc. financial history by metric
About Contineum Therapeutics, Inc.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Contineum Therapeutics, Inc. — frequently asked questions
What is Contineum Therapeutics, Inc.'s revenue?
Contineum Therapeutics, Inc. (CTNM) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Contineum Therapeutics, Inc. profitable?
No — CTNM reported a net loss of $-59.98M in fiscal 2025.
What is CTNM's P/E ratio?
Contineum Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Contineum Therapeutics, Inc. have?
As of fiscal year 2025, CTNM carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Contineum Therapeutics, Inc.'s market cap?
Contineum Therapeutics, Inc. (CTNM) has a market capitalization of about $435.93M, based on the latest data in our nightly-refreshed cache.
When does Contineum Therapeutics, Inc.'s fiscal year end?
CTNM's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Contineum Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.